Bruce Morimoto

Bruce Morimoto, PhD, brings over 25 years of industry experience in leading project teams in the development of innovative medicines, providing guidance in the design and execution of manufacturing, nonclinical, clinical and regulatory strategies with a therapeutic focus on CNS indications including Parkinson’s, Alzheimer’s and frontotemporal dementias. Previously, Bruce held leadership roles at Cerecin, Alkahest, Celerion and Allon Therapeutics, and works closely as a scientific advisor to the Michael J. Fox Foundation, chairing one of their scientific review panels. Bruce started his career on the faculty in the Chemistry Department at Purdue University, where his independent research focused on neuronal signal transduction. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.